IL-2 activated killer cell activity is associated with the early phase of allograft rejection.
Kamholz
S
S
Department of Medicine, SUNY Health Science Center, Brooklyn 11203.
Roslin
M
M
Mondragon
M
M
Coons
M
M
Tranbaugh
R
R
Strashun
A
A
Manjoney
D
D
Norin
A
A
D000818:Animals; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D004285:Dogs; D006084:Graft Rejection; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D016040:Lung Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation; D014184:Transplantation, Homologous
D007376:Interleukin-2